Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio^® in Phase III ENABLAR-2 Trial

Veru, Inc. announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and company which will evaluate the efficacy and safety of enobosarm in combination with Lilly’s abemaciclib as a second line therapy in the treatment of AR+ER+HER2- metastatic breast cancer